CD8A and melanoma: While combined ICI immunotherapy in mice bearing wild-type melanomas potently enhanced the frequency of circulating tumor model antigen OVA-specific CD8+ T cells, this therapy-induced beneficial effect was largely abrogated in mice bearing MLKL−/− tumors (figure 3D).